Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double‐blind, placebo‐controlled, crossover study, with an open‐label extension
Abstract Introduction Cerebral glucose and insulin metabolism is impaired in Alzheimer's disease (AD). Ketones provide alternative energy. Will medium chain triglyceride (MCT) oil, a nutritional source of ketones, impact cognition in AD? Methods This was a 6‐month randomized, double‐blind, plac...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.12259 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846142304813842432 |
|---|---|
| author | Angela G. Juby Toni E. Blackburn Diana R. Mager |
| author_facet | Angela G. Juby Toni E. Blackburn Diana R. Mager |
| author_sort | Angela G. Juby |
| collection | DOAJ |
| description | Abstract Introduction Cerebral glucose and insulin metabolism is impaired in Alzheimer's disease (AD). Ketones provide alternative energy. Will medium chain triglyceride (MCT) oil, a nutritional source of ketones, impact cognition in AD? Methods This was a 6‐month randomized, double‐blind, placebo‐controlled, crossover study, with 6‐month open‐label extension in probable AD subjects, on stable medications. MCT dose was 42 g/day, or maximum tolerated. Cognition was assessed with Mini‐Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Cognigram®. Results Twenty subjects, average age 72.6 years, 45% women, 70% university educated had baseline MMSE 22.6/30 (10–29); MoCA 15.6/30 (4–27); baseline Cognigram® Part 1: 65–106, Part 2: 48–107. Average MCT oil consumption was 1.8 tablespoons/day (25.2 g, 234 kcal). Eighty percent remained stable or improved. Longer MCT exposure and age > 73, resulted in higher final MMSE (P < .001) and Cognigram® 1 scores. Discussion This is the longest duration MCT AD study to date. Eighty percent had stabilization or improvement in cognition, and better response with 9‐month continual MCT oil. |
| format | Article |
| id | doaj-art-cd7bf40d093f4462a8c841909f130d0b |
| institution | Kabale University |
| issn | 2352-8737 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| spelling | doaj-art-cd7bf40d093f4462a8c841909f130d0b2024-12-03T12:37:31ZengWileyAlzheimer’s & Dementia: Translational Research & Clinical Interventions2352-87372022-01-0181n/an/a10.1002/trc2.12259Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double‐blind, placebo‐controlled, crossover study, with an open‐label extensionAngela G. Juby0Toni E. Blackburn1Diana R. Mager2Division of Geriatrics, Department of Medicine, Faculty of Medicine and Dentistry University of Alberta Edmonton Alberta CanadaDivision of Geriatrics, Department of Medicine, Faculty of Medicine and Dentistry University of Alberta Edmonton Alberta CanadaDepartment of Agriculture, Food and Nutrition Science University of Alberta Edmonton Alberta CanadaAbstract Introduction Cerebral glucose and insulin metabolism is impaired in Alzheimer's disease (AD). Ketones provide alternative energy. Will medium chain triglyceride (MCT) oil, a nutritional source of ketones, impact cognition in AD? Methods This was a 6‐month randomized, double‐blind, placebo‐controlled, crossover study, with 6‐month open‐label extension in probable AD subjects, on stable medications. MCT dose was 42 g/day, or maximum tolerated. Cognition was assessed with Mini‐Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), and Cognigram®. Results Twenty subjects, average age 72.6 years, 45% women, 70% university educated had baseline MMSE 22.6/30 (10–29); MoCA 15.6/30 (4–27); baseline Cognigram® Part 1: 65–106, Part 2: 48–107. Average MCT oil consumption was 1.8 tablespoons/day (25.2 g, 234 kcal). Eighty percent remained stable or improved. Longer MCT exposure and age > 73, resulted in higher final MMSE (P < .001) and Cognigram® 1 scores. Discussion This is the longest duration MCT AD study to date. Eighty percent had stabilization or improvement in cognition, and better response with 9‐month continual MCT oil.https://doi.org/10.1002/trc2.12259betahydroxybutyratecoconut oilcognigramCognitive Impairmentcomputer based cognitive testingketones |
| spellingShingle | Angela G. Juby Toni E. Blackburn Diana R. Mager Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double‐blind, placebo‐controlled, crossover study, with an open‐label extension Alzheimer’s & Dementia: Translational Research & Clinical Interventions betahydroxybutyrate coconut oil cognigram Cognitive Impairment computer based cognitive testing ketones |
| title | Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double‐blind, placebo‐controlled, crossover study, with an open‐label extension |
| title_full | Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double‐blind, placebo‐controlled, crossover study, with an open‐label extension |
| title_fullStr | Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double‐blind, placebo‐controlled, crossover study, with an open‐label extension |
| title_full_unstemmed | Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double‐blind, placebo‐controlled, crossover study, with an open‐label extension |
| title_short | Use of medium chain triglyceride (MCT) oil in subjects with Alzheimer's disease: A randomized, double‐blind, placebo‐controlled, crossover study, with an open‐label extension |
| title_sort | use of medium chain triglyceride mct oil in subjects with alzheimer s disease a randomized double blind placebo controlled crossover study with an open label extension |
| topic | betahydroxybutyrate coconut oil cognigram Cognitive Impairment computer based cognitive testing ketones |
| url | https://doi.org/10.1002/trc2.12259 |
| work_keys_str_mv | AT angelagjuby useofmediumchaintriglyceridemctoilinsubjectswithalzheimersdiseasearandomizeddoubleblindplacebocontrolledcrossoverstudywithanopenlabelextension AT tonieblackburn useofmediumchaintriglyceridemctoilinsubjectswithalzheimersdiseasearandomizeddoubleblindplacebocontrolledcrossoverstudywithanopenlabelextension AT dianarmager useofmediumchaintriglyceridemctoilinsubjectswithalzheimersdiseasearandomizeddoubleblindplacebocontrolledcrossoverstudywithanopenlabelextension |